Amferia Kills Bacteria

Executive Summary

Amferia Kills Bacteria, a Swedish biotech founded in 2018, has developed a proprietary antimicrobial hydrogel platform based on antimicrobial peptides (AMPs) that mimic the human immune system. This technology is designed to provide non-toxic, safe, and effective antibacterial solutions for medical devices and wound care. The company's first commercial product is a veterinary wound dressing, which validates its platform in a real-world setting. A key milestone is the FDA De Novo classification for its human wound dressing, positioning Amferia to address the significant unmet need in chronic wound infections and medical device-related infections. With a growing pipeline and strong intellectual property, Amferia is poised for commercialization and strategic partnerships. The company's innovative approach could disrupt the traditional antimicrobial market, offering a solution to rising antibiotic resistance.

Upcoming Catalysts (preview)

• Q3 2026Initiation of pivotal clinical trial for AMP hydrogel in chronic wounds70% success
• Q4 2026First commercial sales of FDA-cleared human wound dressing60% success
• Q2 2026Strategic partnership or licensing deal with a major medical device company50% success